1	Title: Human broncho	pulmonary di	sposition and	plasma	pharmacokinetics	s of oral

# 2 bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19

- 3
- 4 Authors:
- 5 Xiao-Jian Zhou,<sup>a,#</sup> Arantxa Horga,<sup>a</sup> Adeep Puri,<sup>b</sup> Lee Winchester,<sup>c</sup> Maureen Montrond,<sup>a</sup> Keith
- 6 Pietropaolo,<sup>a</sup> Bruce Belanger,<sup>a</sup> Courtney V. Fletcher,<sup>c</sup> Janet Hammond<sup>a</sup>
- 7
- 8 Affiliations:
- 9 <sup>a</sup>Atea Pharmaceuticals, Inc., Boston, Massachusetts, USA
- 10 <sup>b</sup>Hammersmith Medicines Research Ltd, London, UK
- <sup>c</sup>Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha,
- 12 Nebraska, USA
- 13
- 14 Running title: Human lung disposition and plasma PK of bemnifosbuvir
- 15
- <sup>#</sup>Address correspondence to Xiao-Jian Zhou, zhou.xj@ateapharma.com

## 17 ABSTRACT

18	Bemnifosbuvir (BEM, AT-527) is a novel oral guanosine nucleotide antiviral drug for the
19	treatment of patients with COVID-19. Direct assessment of drug disposition in the lungs, via
20	bronchoalveolar lavage, is necessary to ensure antiviral drug levels at the primary site of
21	SARS-CoV-2 infection are achieved. We conducted a Phase 1 study in healthy subjects to
22	assess the bronchopulmonary pharmacokinetics, safety, and tolerability of repeated doses
23	of BEM. A total of 24 subjects were assigned to receive twice-daily (BID) BEM at doses of
24	275, 550, or 825 mg for up to 3.5 days. AT-511, the free base of BEM, was largely eliminated
25	from the plasma within 6 h post dose in all dosing groups. Antiviral drug levels of BEM were
26	consistently achieved in the lungs with BEM 550 mg BID. The mean level of the guanosine
27	nucleoside metabolite AT-273, the surrogate of the active triphosphate metabolite of the
28	drug, measured in the epithelial lining fluid of the lungs was 0.62 $\mu M$ at 4–5 h post dose.
29	This exceeded the target <i>in vitro</i> 90% effective concentration (EC <sub>90</sub> ) of 0.5 $\mu$ M for antiviral
30	drug exposure against SARS-CoV-2 replication in human airway epithelial cells. BEM was
31	well tolerated across all doses tested, and most treatment-emergent adverse events
32	reported were mild in severity and resolved. The favorable pharmacokinetics and safety
33	profile of BEM demonstrates its potential as an oral antiviral treatment for COVID-19, with
34	550 mg BEM BID currently under further clinical evaluation in patients with COVID-19.

35

### 36 INTRODUCTION

- 37 The COVID-19 pandemic caused by SARS-CoV-2 continues to be a worldwide public-health
- 38 concern, with more than 6.9 million confirmed deaths reported globally according to the
- 39 World Health Organization (https://www.who.int/emergencies/diseases/novel-coronavirus-
- 40 2019). SARS-CoV-2 infects the respiratory tract and, although the nasopharynx is an initial
- 41 portal of entry and site of infection commonly used in testing, it is infection of the lower
- 42 airway and lungs that results in substantial mortality (1-4). Effective drug delivery to the
- 43 critical site of infection and prevention of disease progression is therefore important for the
- 44 treatment of COVID-19. Currently, remdesivir and nirmatrelvir/ritonavir are the only
- 45 antiviral drugs approved by the FDA for the treatment of COVID-19, and molnupiravir has
- 46 received emergency use authorization by the FDA (<u>https://www.fda.gov/news-</u>

47 <u>events/press-announcements/fda-approves-first-treatment-covid-19;</u>

- 48 <u>https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-</u>
- 49 treatment-covid-19-adults; https://www.fda.gov/news-events/press-


50 <u>announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-</u>

51 <u>treatment-covid-19-certain</u>). However, remdesivir is not suitable for oral delivery due to its

- rapid clearance, and is limited to use in a hospital or alike setting due to intravenous
- 53 infusion as the only route of administration (5-7). Many drug–drug interactions between
- 54 nirmatrelvir/ritonavir and concomitant medications have been identified in patients with
- 55 COVID-19 (8-11). Furthermore, uncertainties regarding the mutagenicity of molnupiravir
- 56 towards mammalian host DNA have been reported, as well as evidence of molnupiravir-
- 57 induced mutations in the virus sequence which could potentially lead to new variants of
- 58 SARS-CoV-2 (12-16). Although the pharmacokinetics (PK) of these antiviral drugs against

59	SARS-CoV-2 have previously been studied (17-19), there is a lack of clinical data regarding
60	the attainment of antiviral drug levels in the lungs, the site of SARS-CoV-2 replication, which
61	can be measured by bronchoalveolar lavage (BAL). Despite the high viral load of SARS-CoV-2
62	in the lung tissue, data suggest that repurposed antiviral drugs used to treat COVID-19 may
63	not reach an effective concentration in the lungs necessary to inhibit viral replication (20,
64	21). Hence, there is an unmet need for direct-acting antivirals that can be widely
65	administered in an outpatient setting and are demonstrated to effectively target the
66	primary site of infection.
67	Bemnifosbuvir (BEM, AT-527) is an orally available guanosine nucleotide prodrug that has
68	demonstrated potent antiviral activity against hepatitis C virus (HCV) and SARS-CoV-2 (22-
69	24). BEM is the hemisulfate salt of AT-511, a novel phosphoramidate protide that is
70	converted after multistep activation to the active 52 triphosphate metabolite AT-9010,
71	which is formed only after intracellular delivery of the prodrug (Figure 1) (23, 24). AT-9010
72	selectively inhibits viral replication by a dual mechanism of action, simultaneously targeting
73	the RNA-dependent RNA polymerase (RdRp) and nidovirus RdRp-associated nucleotidyl
74	transferase (NiRAN) domains of the SARS-CoV-2 RNA polymerase, resulting in potent
75	inhibition of viral RNA synthesis (25). Dephosphorylation of AT-9010 results in the formation
76	of the guanosine nucleoside metabolite AT-273, which is regarded as a surrogate plasma
77	marker for intracellular concentrations of AT-9010 (24).
78	Once daily (QD) dosing of BEM up to 550 mg in healthy volunteers and HCV-infected
79	patients has previously been assessed in two clinical trials (ClinicalTrials registration no.
80	NCT03219957; ClinicalTrials registration no. NCT04019717). Although the human PK profile
81	reported for BEM in HCV-infected patents is also likely to be observed in patients with

82	COVID-19, epithelial lining fluid (ELF) and the alveolar macrophages (AM) that reside in the
83	ELF are important sites of infection in COVID-19, and therefore information about drug
84	concentrations in the extracellular and intracellular compartments of the lung is essential
85	for development of a drug targeting lower respiratory tract infections.
86	This Phase 1 study was designed to evaluate antiviral drug levels of BEM in the lungs of
87	healthy volunteers using BAL to demonstrate attainment of antiviral drug levels at the
88	primary site of SARS-CoV-2 infection, and to assess the safety and tolerability of BEM when
89	given as repeated oral doses. Dosing of BEM was informed by the previously predicted lung
90	exposure of its active triphosphate metabolite AT-9010, using plasma levels of its surrogate
91	nucleoside metabolite AT-273, to exceed the <i>in vitro</i> 90% effective concentration (EC $_{90}$ ) of
92	0.5 $\mu$ M BEM for inhibition of SARS-CoV-2 replication (24, 26). BEM 550 mg twice daily (BID)
93	was expected to produce sustained lung exposure to AT-9010 greater than the
94	concentration required to inhibit SARS-CoV-2 replication in human airway epithelial (HAE)
95	cells <i>in vitro</i> (24). Although the 550 mg BID regimen was believed to be optimal, a lower and
96	higher dose were also evaluated so that a dose-response relationship could be established.
97	Figure 1. Activation pathway of BEM (AT-527).





100	52-NTase, 52-nucleotidase; ADALP1	adenosine deaminase-like protein 1; BEM	, bemnifosbuvir; CatA, cathepsin A; CES1,
-----	-----------------------------------	---	---

- 101 carboxylesterase 1; GUK1, guanylate kinase 1; HINT1, histidine triad nucleotide binding protein 1; MP, monophosphate;
- 102 NDPK, nucleoside-diphosphate kinase.
- 103
- 104 **RESULTS**
- 105 Subject demographics and baseline characteristics
- 106 A total of 24 healthy subjects entered and completed the trial, and no subjects were
- 107 withdrawn. All enrolled subjects were included in the safety population, PK concentration
- 108 population, and PK parameter population. Demographics and baseline characteristics are
- summarized in **Table 1**. The groups across dosing levels were generally comparable, with sex
- being the only notable difference across dosing levels: one woman (12.5%) received 275 mg
- 111 BEM BID, while an equal number of men and women (four each per dose) received the
- other dose levels (550 mg and 825 mg BID). There were no other notable demographic
- differences between groups. No subjects identified their ethnicity as Hispanic or Latino.

## 114 Table 1. Baseline characteristics of study subjects.

Variable	275 mg BEM BID n=8	550 mg BEM BID n=8	825 mg BEM BID n=8	All subjects N=24
Mean age, years (range)	42.3 (23–64)	44.0 (27–62)	40.6 (21–64)	42.3 (21–64)
Female, n (%)	1 (12.5)	4 (50.0)	4 (50.0)	9 (37.5)
Male, n (%)	7 (87.5)	4 (50.0)	4 (50.0)	15 (62.5)
Race, n (%)				
Black or African American	0	0	2 (25.0)	2 (8.3)
White	8 (100.0)	8 (100.0)	5 (62.5)	21 (87.5)
Other	0	0	1 (12.5)	1 (4.2)
Mean weight, kg (range)	79.1 (67.2–96.4)	72.2 (56.4–94.5)	69.5 (56.6–83.3)	73.6 (56.4–96.4)
Mean BMI, kg/m <sup>2</sup> (range)	24.4 (20.1–27.9)	25.2 (22.8–27.9)	23.8 (20.8–26.0)	24.5 (20.1–27.9)

115 BEM, bemnifosbuvir; BID, twice daily; BMI, body mass index.


# 117 Safety and tolerability

118	BEM was well tolerated across all doses, and no serious adverse events (SAEs) or adverse
119	events (AEs) leading to discontinuation were observed during the study. 11 subjects (45.8%)
120	reported at least one treatment-emergent adverse event (TEAE) after the start of BEM
121	dosing (17 reported in total). Of the 11 subjects reporting a TEAE, two subjects (25.0%) had
122	received 275 mg, three (37.5%) had received 550 mg, and six (75.0%) had received 825 mg
123	BEM BID. The most frequently reported TEAEs were nausea (n=2; 825 mg BEM BID),
124	esophageal mucosa erythema (n=2; 825 mg BEM BID), and oropharyngeal pain (n=2; one
125	each at 275 mg and 825 mg BEM BID). All other TEAEs were reported in one subject each
126	(dizziness, headache, lethargy, paresthesia, tremor, chest pain, pyrexia, vessel puncture site
127	bruise, increased C-reactive protein [CRP] and leukocyte count, and back pain). The severity
128	of most TEAEs was considered to be mild, except for three that were Grade 2 in severity
129	(headache, chest pain, and pyrexia), each reported by one subject per dosing level. Of the
130	17 TEAEs reported, two (both mild nausea) were considered to be possibly related to the
131	study drug, both after the second dose of 825 mg BEM BID and lasting 1–2 h. Three TEAEs
132	had unknown outcomes and were reported during subjects' final follow-up visit (lethargy
133	and two instances of esophageal mucosa erythema), and all other TEAEs resolved. One
134	subject who received 825 mg BEM BID reported a fever after the final dose, approximately 4
135	h after bronchoscopy, although this was likely a side effect of the midazolam sedation
136	medication used during bronchoscopy. The fever coincided with a high leukocyte count and
137	raised CRP level, which was considered clinically significant; however, the leukocyte count
138	was within the reference range at all other timepoints and the CRP level returned to normal
139	by the time of the subject's follow-up visit.

# 140 Plasma PK

141	Mean (± standard deviation [SD]) plasma concentration-time profiles for AT-511 and the
142	guanosine nucleoside metabolite AT-273 (surrogate of the intracellular active triphosphate
143	AT-9010) are presented in <b>Figure 2</b> . The mean AT-511 plasma concentration-time curves
144	were similar in shape after the last dose of 275 mg, 550 mg, and 825 mg BEM BID.
145	Plasma PK parameters of AT-511 and AT-273 are summarized in Table 2. AT-511 was rapidly
146	absorbed in plasma after oral dosing, with the rate of absorption unaffected by dose:
147	median time to maximum plasma concentration ( $t_{max}$ ) was 0.5 h after all doses of BEM. AT-
148	511 was largely eliminated from plasma within 6 h post dose with a short half-life of
149	approximately 1 h in all dosing groups, and the concentration-time profile was consistent
150	with first-order PK. Mean maximum plasma concentration ( $C_{max}$ ) and area under plasma
151	concentration–time curve during a dosing interval (AUC $_{ au}$ ) of AT-511 increased more than
152	proportionally at the lower dosing levels of 275 mg and 550 mg BEM BID, and less than
153	proportionally at the higher dosing levels of 550 mg and 825 mg BEM BID.
154	

- 155 Figure 2. Mean (± SD) plasma concentration-time profiles of AT-511 (A) and AT-273 (B) on
- the last dosing day up to 12 h post dose of 275 mg, 550 mg, and 825 mg BEM dosage
- 157 regimens (inserts: semi-log plots with no SD for clarity).



- 159 BEM, bemnifosbuvir; BID, twice daily; SD, standard deviation.
- 160 '0 h' is pre dose (morning), '4 h' is 4 h or pre BAL (4–5 h, as applicable), and '10 h' is pre BAL (11–12 h). Values below the
- 161 limit of quantification are imputed to 0.
- 162 Panel A: At each dose level, n=8 except at 10 h (n=4).

### 163 **Table 2. Summary of repeat dose plasma PK parameters of AT-511 and AT-273: PK**

			AT-511			AT-273	
PK parame	ter	275 mg BEM BID (2.5 days)	550 mg BEM BID (2.5 days)	825 mg BEM BID (3.5 days)	275 mg BEM BID (2.5 days)	550 mg BEM BID (2.5 days)	825 mg BEM BID (3.5 days)
C <sub>max</sub>	Mean	415	2970	3040	142	285	313
(ng/mL)	(± SD) <sup>a</sup>	(411)	(2364)	(1185)	(37.2)	(74.4)	(101)
t <sub>max</sub> (h)	Median	0.50	0.50	0.50	3.00	3.00	4.00
	Range	0.50–1.00	0.50–2.00	0.50–1.00	0–4.00	0-6.17	0-4.10
AUCτ	Mean	504	2695	3306	1354	2640	2935
(ng·h/mL)	(± SD) <sup>a</sup>	(647)	(2061)	(1451)	(315)	(731)	(998)
t <sub>1/2</sub> (h)	Mean (± SD)ª	0.81 (0.27)	1.00 (0.19)	1.17 (0.36)	$ND^{b}$	$ND^{b}$	ND <sup>b</sup>

### 164 parameter population.

<sup>a</sup>Arithmetic mean. <sup>b</sup>Not determined due to sampling time limited to dosing interval.

166 AUCτ, area under the concentration-time curve (AUC) during a dosing interval; BEM, bemnifosbuvir; BID, twice daily; C<sub>max</sub>,

167 maximum plasma concentration; PK, pharmacokinetic; SD, standard deviation; t<sub>1/2</sub>, half-life; t<sub>max</sub>, time to maximum plasma

- 168 concentration.
- 169 N=8 for all dose levels.
- 170

171 After BEM BID, median  $t_{max}$  of AT-273 was 3–4 h across dose levels. Mean  $C_{max}$  and AUC<sub>t</sub> of

172 AT-273 increased proportionally with dose. The mean (± SD) trough plasma concentrations

173 (C<sub>trough</sub>) of AT-273 at 12 h after the final dose of 275 mg, 550 mg, and 825 mg BEM BID were

174 92.1 (27.2), 168.0 (51.8), and 144.7 (47.6) ng/mL, respectively. Plasma concentrations of AT-

175 273 were sustained without much fluctuation and consistently exceeded the target level of

176 150 ng/mL (0.5 μM, EC<sub>90</sub> of the drug for inhibiting SARS-CoV-2 replication in HAE cells *in* 

177 *vitro*) over the dose interval with BEM 550 mg BID (Figure 2).

## 178 ELF and time-matched plasma concentrations

179 Mean (± SD) ELF and time-matched plasma concentrations of AT-273 are presented in Table

180 **3**. All AT-511 concentrations in ELF were below the limit of quantification (BLQ), except for

181 one subject who had an AT-511 concentration of 10.5 ng/mL in ELF on Day 4, at the 4–5 h

- 182 BAL timepoint. Concentrations of AT-273 were quantifiable in BAL fluid supernatant (BALF)
- at the two highest dose levels of BEM (550 mg and 825 mg BID), regardless of BAL
- 184 timepoint. After 275 mg BEM BID, three of four subjects who had their BAL at 11–12 h post
- dose had quantifiable AT-273 in BALF, but all four of those who had their BAL at 4–5 h post
- dose did not. Overall, ELF AT-273 concentrations were higher among subjects who had their
- 187 BAL procedure at 4–5 h post dose than in those who had BAL at 11–12 h post dose,
- approximately corresponding to the peak and trough plasma levels.

### **Table 3. Mean (± SD) comparative ELF vs plasma concentrations of AT-273.**

	AT-273 concentration	Sampling time (h)			
Dose	(ng/mL)	Day 3 or 4ª 4–5 h	Day 3 or 4ª 11–12 h		
	Mean ELF (± SD)	0	53.3 (44.2)		
275 mg BEM BID (2.5 days)	Mean plasma (± SD)	117 (21.4)	92.1 (27.2)		
(2.5 6495)	Ratio (± SD)	0	0.72 (0.10) <sup>b</sup>		
	Mean ELF (± SD)	185 (89.6)	138 (76.0)		
550 mg BEM BID (2.5 days)	Mean plasma (± SD)	240 (39.4)	168 (51.8)		
(210 00 90)	Ratio (± SD)	0.76 (0.30)	0.79 (0.18)		
825 mg BEM BID	Mean ELF (± SD)	197 (96.2)	103 (24.0)		
(3.5 days)	Mean plasma (± SD)	330 (110)	145 (47.6)		
	Ratio (± SD)	0.58 (0.20)	0.73 (0.09)		

<sup>&</sup>lt;sup>1</sup>90 <sup>a</sup>Last dosing day was on Day 3 for Groups 1 and 2 (275 and 550 mg BID) and on Day 4 for Group 3 (825 mg BID). <sup>b</sup>n=3.

191 BEM, bemnifosbuvir; BID, twice daily; ELF, epithelial lining fluid; SD, standard deviation.

194 correcting the values for (plasma/BALF) urea ratio.


195 At the 550 mg BEM BID dose, mean ELF levels of AT-273 at the 4–5 h and 11–12 h BAL

- 196 timepoints were 185 and 138 ng/mL (0.62 and 0.46 μM), respectively (exceeding or
- 197 approaching the target level of 150 ng/mL or 0.5 μM). Similarly, at the 825 mg BEM BID
- dose, mean ELF levels of AT-273 at the 4–5 h and 11–12 h BAL timepoints were 197 and 103

<sup>192 0.5</sup> μM equivalent to 150 ng/mL for AT-273. Half of each cohort had the BAL procedure 4–5 h after dosing, the other half

<sup>193</sup> at 11–12 h after dosing. At each dose level, n=8 except at 11–12 h (n=4). ELF concentrations BLQ were imputed to 0 before

- 199 ng/mL (0.66 and 0.34 μM), respectively. Mean ratios of ELF-to-plasma concentrations were
- 200 generally below 1 (range of 0.58 to 0.78). There was a significant correlation between ELF
- and plasma levels of AT-273 (r<sup>2</sup>=0.6777, p<0.0001) (Figure 3).
- 202 Figure 3. Correlation between plasma and ELF AT-273 levels.



203

204 BID, twice daily; ELF, epithelial lining fluid.

- 205 ELF AT-273 levels with 275 mg BID at the 4 h timepoint were BLQ and therefore excluded.
- 206 AT-9010 concentrations
- 207 AM samples for the 275 mg and 550 mg BEM BID doses were left at room temperature
- without dry ice for 11 days (May 24 to June 4, 2021) during transfer, resulting in degradation
- 209 of AT-9010 and making data uninterpretable. After 825 mg BEM BID, AT-9010 in AM was
- 210 quantifiable (>lower limit of quantification [LLQ] at 3.34 fmol) in all but one subject who had

211 their BAL at 11–12 h post dose. In the remaining subjects, AT-9010 concentrations in AM

212 ranged from 0.79 to 5.37 nM.

213

### 214 **DISCUSSION**

215	The PK of orally administered BEM has previously been reported in HCV-infected patients,
216	and briefly described in healthy subjects and patients with COVID-19 (22, 26, 27); however,
217	the delivery to the lungs of BEM or any other direct-acting antivirals against SARS-CoV-2 has
218	not previously been studied. This study describes the first results of a Phase 1 study
219	assessing the intrapulmonary disposition and plasma PK of BEM following various doses in
220	healthy adults. BEM was well tolerated across all doses of 275, 550, and 825 mg BID tested
221	in healthy volunteers, with no clinically significant physical examination findings, vital signs,
222	or electrocardiogram (ECGs) observed. There were no deaths, non-fatal SAEs, nor other
223	significant AEs or AEs leading to subject withdrawal from treatment during the study. All
224	TEAEs reported were mild or moderate in severity. The overall rate of TEAEs reported
225	increased with increasing doses of BEM, with 25% of subjects reporting mild nausea after
226	825 mg BEM BID, which was considered as possibly related to the study drug. Two clinically
227	significant laboratory results were reported in one subject receiving 825 mg BEM BID (high
228	leukocyte count and raised CRP) coinciding with a fever; however, these symptoms were
229	considered likely a result of the midazolam sedation used during bronchoscopy. BEM was
230	well tolerated at the 550 mg BID dose, with no gastrointestinal TEAEs reported. This is
231	consistent with the favorable safety profile of 550 mg BEM previously observed in HCV-
232	infected subjects (22), the administration of 550 mg BEM QD in combination with
233	daclatasvir for up to 12 weeks (28), and 550 mg BID BEM for 5 days assessed in both

hospitalized patients with moderate COVID-19 and non-hospitalized patients with mild-to-

235 moderate COVID-19 (29, 30).

236	As designed, AT-511, a phosphoramidate protide, exhibited a very transient plasma profile
237	with fast absorption followed by rapid multistep activation to the intracellular antiviral
238	triphosphate AT-9010. The active triphosphate was then dephosphorylated to the
239	guanosine nucleoside metabolite, AT-273, which entered general circulation. As AT-273
240	cannot efficiently be anabolized to its phosphorylated forms, circulating AT-273 is therefore
241	considered a surrogate of AT-9010. Oral dosing of BEM 550 mg BID resulted in sustained
242	plasma levels of AT-273, which consistently exceeded the target of 150 ng/mL or 0.5 $\mu$ M,
243	the <i>in vitro</i> EC <sub>90</sub> of AT-511 for inhibiting SARS-CoV-2 replication in HAE cells.
244	The BAL samples were obtained at 4–5 h and 11–12 h post dose to capture the maximum
245	and trough ELF levels of AT-273. Due to its rapid clearance, AT-511 was not expected to be
246	frequently measurable at these timepoints in the BAL fractions. In fact, AT-511
247	concentrations in BAL samples were BLQ in all but one subject. By contrast, AT-273
248	concentrations were mostly quantifiable in BAL samples, especially with the 550 mg BID and
249	825 mg BID doses. The 275 mg BID dose, however, did not achieve sufficient AT-273 levels.
250	BEM 550 mg BID achieved ELF levels of AT-273, surrogate of AT-9010, exceeding or
251	approaching the target 150 ng/mL or 0.5 $\mu$ M at 4–5 h and 11–12 h, providing direct
252	evidence that BEM 550 mg BID produced antiviral drug exposure in the lungs and confirming
253	previously predicted lung AT-9010 levels with this regimen (24). The 825 mg BID regimen
254	also produced ELF AT-273 levels exceeding the target at 4–5 h, but increased less than dose-
255	proportionally from the 550 mg BID dose. ELF and plasma levels of AT-273 were found to be
256	significantly correlated, potentially allowing for prediction of ELF levels from plasma

257	samples, which are more commonly available. This relationship, taken together with
258	previous results showing that plasma levels of AT-273 rapidly increased to exceed the target
259	150 ng/mL within a few hours of the first dose of BEM 550 mg BID (26, 27), suggests that
260	BEM produced antiviral drug exposure in the lungs shortly following initiation of treatment.
261	Since direct-acting antivirals are most effective when administered during the early stage of
262	SARS-CoV-2 infection (7), high antiviral drug levels in the lungs achieved early after
263	administration of BEM 550 mg BID are of particular relevance to a better treatment
264	outcome. This is supported by the findings that BEM 550 mg BID for 5 days reduced
265	hospitalization rates in patients with COVID-19 by 71% compared with placebo (n=207)
266	(ClinicalTrials registration no. NCT04889040) (30).
267	In summary, the results of this study provide important information on the PK disposition of
268	oral BEM in the lungs of healthy subjects assessed by BAL, which is the primary site of SARS-
269	CoV-2 infection. We have confirmed the formation of AT-9010, the active triphosphate
270	metabolite of BEM, in alveolar macrophages and demonstrated that the dosing regimen of
271	550 mg BEM BID achieved the target antiviral drug exposure in the lungs of 0.5 $\mu$ M EC $_{90}$
272	against SARS-CoV-2 replication, with a mean AT-273 ELF concentration of 0.62 $\mu M$ at BAL
273	taken 4–5 h post dose, exceeding the target antiviral level. In addition to the favorable PK
274	demonstrated, BEM was well tolerated, with no significant AEs reported. BEM is therefore
275	an attractive antiviral treatment for COVID-19, and the oral route of administration allows
276	for use in the outpatient setting. A global Phase 3 clinical trial (ClinicalTrials registration no.
277	NCT05629962) is currently ongoing to evaluate the safety and efficacy of oral BEM 550 mg
278	BID for the treatment of high-risk outpatients with COVID-19.
279	

### 280 MATERIALS AND METHODS

# 281 Study design and subjects

282	This was a Phase 1, open-label study to assess the bronchopulmonary PK, safety, and
283	tolerability of repeated doses of BEM in healthy subjects (ClinicalTrials.gov registration no.
284	NCT04877769). Healthy adult subjects between the ages of 18 and 65 who met the inclusion
285	and exclusion criteria were considered eligible for this study. All subjects were required to
286	have an initial screening that included clinical history, physical examination, 12-lead ECG,
287	vital signs, spirometry, and laboratory tests of blood and urine. A follow-up visit was
288	scheduled for 7 days after the last dose. All subjects were required to weigh at least 50 kg
289	and have a body mass index of between 18 and 29 kg/m <sup>2</sup> , inclusive. Subjects were also
290	required to have a forced expiratory volume (FEV <sub>1</sub> ) and forced vital capacity (FVC) $\ge$ 80% of
291	predicted value and FEV $_1$ /FVC ratio >0.7 within 28 days before their first dose of trial
292	medication. Exclusion criteria included clinically relevant abnormal medical history, physical
293	findings, ECG, or laboratory values at the pre-trial screening assessment; positive test for
294	SARS-CoV-2 or suspected exposure to the SARS-CoV-2 virus during the 14 days before
295	screening; receipt of a vaccine against COVID-19 in the 14 days before the first dose; or
296	scheduled to receive a dose of the vaccine 2 weeks after the last dose. Subjects could not
297	have received a prescription medicine during the 28 days before the first dose, and no over-
298	the-counter medicine or herbal or dietary supplements were permitted during the 7 days
299	before the first dose. Subjects with positive tests for hepatitis B antigen, hepatitis C, or
300	human immunodeficiency virus were excluded. Subjects were allocated to receive either
301	550 mg of BEM for 2.5 days (Group 1), 275 mg of BEM for 2.5 days (Group 2), or 825 mg

302 BEM for 3.5 days (Group 3), up to seven doses in total. Each dose was administered orally as

303 either one or three tablets and taken with approximately 240 mL water.

304 The study protocol was approved by the UK Medicines and Healthcare products Regulatory

- 305 Agency and West Midlands Edgbaston Research Ethics Committee before the trial began,
- and written informed consent was obtained from each subject.
- 307 Blood sample collection for plasma PK and urea
- 308 Blood samples (3 mL/timepoint) were obtained to determine drug and urea concentrations.
- 309 On the day of BAL procedure (Day 3 for Groups 1 and 2; Day 4 for Group 3), serial blood
- samples for assay of plasma drug levels were taken before the final dose and 0.5, 1, 2, 3, 4,
- 6, 8, and 12 h post dose. For all groups, blood samples were also taken immediately before
- the bronchoscopy (performed at 4–5 h or 11–12 h after final dose) for assay of BAL time-
- 313 matched plasma drug and urea levels. Blood samples were collected and immediately
- placed on ice, and centrifuged at  $1500 \times g$  for 10 min at 4°C. After centrifugation, the plasma
- 315 was divided into two aliquots and snap frozen on dry ice within 60 min of collection, then
- stored at -80°C until analyzed. Analysis of AT-511 and metabolites was performed by
- 317 Altasciences Company, Inc (Laval, Quebec, Canada), and urea analysis was performed by
- 318 MicroConstants, Inc (San Diego, CA, USA).

## 319 Bronchoscopy and BAL

BAL samples were taken 4–5 h and 11–12 h after dosing on Day 3 (Groups 1 and 2) or Day 4

321 (Group 3). The subjects were prepared with 6% lidocaine gel for nasal local anesthesia and

- lubrication. Midazolam 1 mg/mL with a 0.9% saline flush was prescribed for sedation if
- needed. The saline for lavage was drawn up in four 50 mL aliquots for a total volume of 200
- 324 mL. Up to four or five BAL samples (BAL 1–5) were collected for each subject. BAL 1 was

325	processed alone, while BAL 2–4 (or BAL 2–5, if a fifth sample was collected) were pooled
326	together for processing. For each of the two resulting samples, $2 \times 4$ mL BAL fluid was sent
327	on ice to the laboratory for cell count and differential, while the remaining BAL fluid was
328	centrifuged at 400 × $g$ for 5 min at 4°C to separate the BALF and pellet. From the BALF, 4 × 2
329	mL aliquots (two for urea and two for PK) were prepared in cryovials and frozen at -80°C.
330	The pellets (containing AM) were resuspended in ice cold 70% methanol solution containing
331	5 mM dibromoacetic acid and frozen on dry ice or at -80°C. The BALF and AM samples were
332	stored at -80°C until shipped, frozen and on dry ice. For the BALF samples, analysis of AT-
333	511 and AT-273 was performed by Altasciences Company, Inc (Laval, Quebec, Canada) and
334	urea analysis was performed by MicroConstants, Inc (San Diego, CA, USA). For the AM
335	samples, analysis of AT-9010 was performed by the University of Nebraska Medical Center
336	(Omaha, NE, USA).
337	AT-511 and AT-273 plasma and BAL assays
337	AT-511 and AT-273 plasma and BAL assays
337 338	AT-511 and AT-273 plasma and BAL assays Concentrations of AT-511 and AT-273 measured in plasma and BAL supernatants were
337 338 339	AT-511 and AT-273 plasma and BAL assays Concentrations of AT-511 and AT-273 measured in plasma and BAL supernatants were determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) (Altasciences
337 338 339 340	AT-511 and AT-273 plasma and BAL assays Concentrations of AT-511 and AT-273 measured in plasma and BAL supernatants were determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) (Altasciences Company, Inc). BAL samples were collected and mixed with an anti-adsorptive agent
337 338 339 340 341	AT-511 and AT-273 plasma and BAL assays Concentrations of AT-511 and AT-273 measured in plasma and BAL supernatants were determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) (Altasciences Company, Inc). BAL samples were collected and mixed with an anti-adsorptive agent solution prior to storage. Following deproteinization with cold acetonitrile and methanol
337 338 339 340 341 342	AT-511 and AT-273 plasma and BAL assays Concentrations of AT-511 and AT-273 measured in plasma and BAL supernatants were determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) (Altasciences Company, Inc). BAL samples were collected and mixed with an anti-adsorptive agent solution prior to storage. Following deproteinization with cold acetonitrile and methanol (1:3), samples were subsequently diluted for injection. Chromatographic separation
337 338 339 340 341 342 343	AT-511 and AT-273 plasma and BAL assays Concentrations of AT-511 and AT-273 measured in plasma and BAL supernatants were determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) (Altasciences Company, Inc). BAL samples were collected and mixed with an anti-adsorptive agent solution prior to storage. Following deproteinization with cold acetonitrile and methanol (1:3), samples were subsequently diluted for injection. Chromatographic separation involved gradient elution on an XBridge C <sub>18</sub> column (50 × 4.6 mm, 3.5 μm) using 10 mM
337 338 339 340 341 342 343 344	AT-511 and AT-273 plasma and BAL assays Concentrations of AT-511 and AT-273 measured in plasma and BAL supernatants were determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) (Altasciences Company, Inc). BAL samples were collected and mixed with an anti-adsorptive agent solution prior to storage. Following deproteinization with cold acetonitrile and methanol (1:3), samples were subsequently diluted for injection. Chromatographic separation involved gradient elution on an XBridge C <sub>18</sub> column (50 × 4.6 mm, 3.5 μm) using 10 mM ammonium bicarbonate and acetonitrile and methanol (1:1) as organic modifier. The LC

1 (LLQ) and 1000 ng/mL for both analytes in plasma, 0.200 (LLQ) and 200 ng/mL for AT-511,

349 and 0.400 (LLQ) and 400 ng/mL for AT-273 in BAL.

### 350 AT-9010 assay

- 351 Concentrations of AT-9010 in AM and other cell populations isolated from the upper airway
- 352 lavage fluid were determined by LC-MS/MS (University of Nebraska Medical Center). Briefly,
- 353 AT-9010 was extracted from cell debris via anion-exchange solid-phase extraction (SPE)
- followed by dephosphorylation to AT-273 via acid phosphatase. AT-273 was desalted by a
- 355 reversed-phase SPE cartridge and analyzed using LC-MS/MS. Chromatographic separation
- was carried out on a Synergi Polar-RP 100 × 2.00 mm column for the stationary phase, using
- 357 5% acetonitrile, 0.1% formic acid in water, with 0.1% formic acid in acetonitrile with
- gradient elution for the mobile phase. AT-273 was detected by an AB Sciex 6500 triple
- 359 quadrupole mass spectrometer in positive ion mode monitoring MRM transition
- 360 300.0>152.1. The analytical range was from 3.34 (LLQ) to 3340 fmol/sample. A mean
- 361 alveolar macrophage cell volume of 2.42  $\mu$ L/10<sup>6</sup> cells was used in calculating AT-9010
- 362 concentrations (31).

### 363 Urea plasma and BAL assays

- 364 Plasma urea concentrations were measured using a colorimetric detection assay with an
- assay range from 2.5 (LLQ) to 50 mg/dL. BAL urea concentrations were quantified using an
- immunoassay with an assay range from 0.15 to 2.5 mg/dL using 150 μL of sample, and from
- 367 0.05 to 1 mg/dL using 300  $\mu$ L of sample.

### 368 Calculation of the volume of ELF and drug concentrations

- 369 Drug levels in lung ELF were calculated by correcting for urea levels in the BAL and the
- 370 corresponding plasma samples as:  $Conc_{ELF} = Conc_{BAL} \times (Urea_{Plasma}/Urea_{BAL})$ , where  $Conc_{ELF}$

- 371 and Conc<sub>BAL</sub> are drug levels in the ELF and BAL, respectively, and Urea<sub>Plasma</sub> and Urea<sub>BAL</sub> are
- 372 the plasma and BAL urea levels, respectively.

### 373 **PK analysis**

- Plasma PK parameters were derived from plasma concentration data, using non-
- 375 compartmental analysis in WinNonLin v8.3. C<sub>max</sub>, T<sub>max</sub>, and C<sub>trough</sub> were calculated directly
- 376 from the concentration-time data. AUC<sub> $\tau$ </sub> after the final dose was calculated using the
- 377 trapezoidal method. The PK concentration data were summarized using the PK
- 378 concentration population and PK parameters were summarized using the PK parameter
- population. The pooled BAL 2–4 samples (or BAL 2–5, where a fifth BAL sample was
- 380 collected) were used for the ratios and summary statistics.

## 381 Statistical analysis

- All statistical analyses were carried out using SAS<sup>®</sup> version 9.4. PK analysis was carried out
- using non-compartmental approaches in WinNonlin version 8.3.

## 384 Laboratory and safety assessment

- 385 Safety was measured by clinical laboratory tests (hematology, biochemistry, coagulation,
- serum chemistry, and urinalysis), physical examination, vital signs, 12-lead ECGs, spirometry,
- 387 SARS-CoV-2 testing, and monitoring of AEs. All AEs were coded using the Medical Dictionary
- for Regulatory Activities (MedDRA) v24.1. Concomitant medications were coded using the
- World Health Organization (WHO) Drug Global coding dictionary (September 2021 version).

# 391 ACKNOWLEDGMENTS

- 392 This study was funded by Atea Pharmaceuticals, Inc and F Hoffmann-LaRoche Ltd. Medical
- 393 writing support was provided by Samantha Brick, Elements Communications Ltd, UK, and
- 394 funded by Atea Pharmaceuticals, Inc.
- 395 Xiao-Jian Zhou, Arantxa Horga, Maureen Montrond, Keith Pietropaolo, Bruce Belanger, and
- 396 Janet Hammond are employees of and may own stock in Atea Pharmaceuticals, Inc, Boston,
- 397 MA, USA; Adeep Puri is an employee of Hammersmith Medicines Research Ltd, London, UK,
- 398 which was contracted to help perform this research; Lee Winchester and Courtney V.
- 399 Fletcher are employees of the University of Nebraska Medical Center, Omaha, NE, USA, and
- 400 were contracted to help perform this research.

### 401 **REFERENCES**

- 402 1. Roque M, Proudfoot K, Mathys V, Yu S, Krieger N, Gernon T, Gokli K, Hamilton S, Cook C,
- 403 Fong Y. 2021. A review of nasopharyngeal swab and saliva tests for SARS-CoV-2
- 404 infection: Disease timelines, relative sensitivities, and test optimization. J Surg Oncol
- 405 124:465-475.
- 406 2. Candel S, Tyrkalska SD, Álvarez-Santacruz C, Mulero V. 2023. The nasopharyngeal
- 407 microbiome in COVID-19. Emerg Microbes Infect 12:e2165970.
- 408 3. Bösmüller H, Matter M, Fend F, Tzankov A. 2021. The pulmonary pathology of COVID-
- 409 19. Virchows Arch 478:137-150.
- 410 4. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, Sinn BV, Gerhold M,
- 411 Hauptmann K, Ingold-Heppner B, Miller F, Herbst H, Corman VM, Martin H, Radbruch H,
- 412 Heppner FL, Horst D. 2021. Causes of death and comorbidities in hospitalized patients
- 413 with COVID-19. Scientific Reports 11:4263.
- 414 5. Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, Ling J, Vu A, German P. 2020.
- 415 Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of
- 416 COVID-19, in Healthy Subjects. Clin Transl Sci 13:896-906.
- 417 6. Wang Z, Yang L, Song XQ. 2022. Oral GS-441524 derivatives: Next-generation inhibitors
- 418 of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol 13:1015355.
- 419 7. Singh M, de Wit E. 2022. Antiviral agents for the treatment of COVID-19: Progress and
- 420 challenges. Cell Rep Med 3:100549.
- 421 8. Conti V, Sellitto C, Torsiello M, Manzo V, De Bellis E, Stefanelli B, Bertini N, Costantino
- 422 M, Maci C, Raschi E, Sabbatino F, Corbi G, Pagliano P, Filippelli A. 2022. Identification of

- 423 Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review. JAMA
- 424 Network Open 5:e227970-e227970.
- 425 9. Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M,
- 426 Waters L, Burger D, Back DJ, Khoo S. 2022. Recommendations for the Management of
- 427 Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid)
- 428 and Comedications. Clin Pharmacol Ther 112:1191-1200.
- 429 10. Saravolatz LD, Depcinski S, Sharma M. 2023. Molnupiravir and Nirmatrelvir-Ritonavir:
- 430 Oral Coronavirus Disease 2019 Antiviral Drugs. Clin Infect Dis 76:165-171.
- 431 11. Petrakis V, Rafailidis P, Trypsianis G, Papazoglou D, Panagopoulos P. 2023. The Antiviral
- 432 Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data. Viruses
- 433 15:976.
- 434 12. Masyeni S, Iqhrammullah M, Frediansyah A, Nainu F, Tallei T, Emran TB, Ophinni Y,
- 435 Dhama K, Harapan H. 2022. Molnupiravir: A lethal mutagenic drug against rapidly
- 436 mutating severe acute respiratory syndrome coronavirus 2-A narrative review. J Med
- 437 Virol 94:3006-3016.
- 438 13. Waters MD, Warren S, Hughes C, Lewis P, Zhang F. 2022. Human genetic risk of
- 439 treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The

440 special case of molnupiravir. Environ Mol Mutagen 63:37-63.


- 14. Malin JJ, Weibel S, Gruell H, Kreuzberger N, Stegemann M, Skoetz N. 2023. Efficacy and
- 442 safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review
- 443 and meta-analysis. Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkad132.


- 444 15. Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang
- 445 M, Mao Q. 2022. Efficacy and safety of three new oral antiviral treatment (molnupiravir,
- fluvoxamine and Paxlovid) for COVID-19 : a meta-analysis. Ann Med 54:516-523.
- 16. Sanderson T, Hisner R, Donovan-Banfield Ia, Hartman H, Løchen A, Peacock TP, Ruis C.
- 448 2023. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
- 449 Nature doi:10.1038/s41586-023-06649-6.
- 450 17. Leegwater E, Moes D, Bosma LBE, Ottens TH, van der Meer IM, van Nieuwkoop C, Wilms
- 451 EB. 2022. Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized
- 452 COVID-19 Patients. Antimicrob Agents Chemother 66:e0025422.
- 453 18. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut N, Morin MJ, Szewczyk LJ,
- 454 Painter GR. 2021. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a
- 455 Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob
- 456 Agents Chemother 65.
- 457 19. Toussi SS, Neutel JM, Navarro J, Preston RA, Shi H, Kavetska O, LaBadie RR, Binks M,
- 458 Chan PLS, Demers N, Corrigan B, Damle B. 2022. Pharmacokinetics of Oral
- 459 Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With
- 460 Renal Impairment. Clin Pharmacol Ther 112:892-900.
- 461 20. Sahin G, Akbal-Dagistan O, Culha M, Erturk A, Basarir NS, Sancar S, Yildiz-Pekoz A. 2022.
- 462 Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19
- 463 Treatment. J Pharm Sci 111:2652-2661.
- 464 21. Wang Y, Chen L. 2020. Lung tissue distribution of drugs as a key factor for COVID-19
- treatment. British Journal of Pharmacology 177:4995-4996.

- 466 22. Berliba E, Bogus M, Vanhoutte F, Berghmans PJ, Good SS, Moussa A, Pietropaolo K,
- 467 Murphy RL, Zhou XJ, Sommadossi JP. 2019. Safety, pharmacokinetics and antiviral
- 468 activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and
- 469 without cirrhosis. Antimicrob Agents Chemother 63.
- 470 23. Good SS, Moussa A, Zhou XJ, Pietropaolo K, Sommadossi JP. 2020. Preclinical evaluation
- 471 of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity
- against hepatitis C virus. PLoS One 15:e0227104.
- 473 24. Good SS, Westover J, Jung KH, Zhou XJ, Moussa A, La Colla P, Collu G, Canard B,
- 474 Sommadossi JP. 2021. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a
- 475 Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of
- 476 COVID-19. Antimicrob Agents Chemother 65.
- 477 25. Shannon A, Fattorini V, Sama B, Selisko B, Feracci M, Falcou C, Gauffre P, El Kazzi P,
- 478 Delpal A, Decroly E, Alvarez K, Eydoux C, Guillemot J-C, Moussa A, Good SS, La Colla P,
- 479 Lin K, Sommadossi J-P, Zhu Y, Yan X, Shi H, Ferron F, Canard B. 2022. A dual mechanism
- 480 of action of AT-527 against SARS-CoV-2 polymerase. Nature Communications 13:621.
- 481 26. Zhou XJ, Horga A, Morelli G, Montrond M, Pietropaolo K, Belanger B, Good SS, Moussa
- 482 A, Hammond J, Sommadossi JP. 2021. High lung levels of active triphosphate predicted
- 483 with oral AT-527 in COVID patients. Topics in Antiviral Medicine 29:127.
- 484 27. Boffito M, Dolan E, Singh K, Holmes W, Wildum S, Horga A, Pietropaolo K, Zhou XJ,
- 485 Clinch B, Collinson N, Ukachukwu V. 2023. A Phase 2 Randomized Trial Evaluating the
- 486 Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory
- 487 Patients with Mild or Moderate COVID-19 (MOONSONG Study). Microbiol Spectr
- 488 doi:10.1128/spectrum.00077-23:e0007723.

489	28. Mungur O	, Berliba E, I	Bourgeois S,	Cardona I	M, Jucov A,	Good S,	Moussa A,	Pietropaolo k	ί,
-----	--------------	----------------	--------------	-----------	-------------	---------	-----------	---------------	----

- 490 Zhou X-J, Brown N. 2020. A combination of AT-527, a pan-genotypic guanosine
- 491 nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected
- 492 subjects. Journal of Hepatology 73:S357.
- 493 29. Horga A, Kuritzkes DR, Kowalczyk JJ, Pietropaolo K, Belanger B, Lin K, Perkins K,
- 494 Hammond J. 2023. Phase II study of bemnifosbuvir in high-risk participants in a hospital
- 495 setting with moderate COVID-19. Future Virology 18:489-500.
- 496 30. Horga A, Saenz R, Yilmaz G, Simón-Campos A, Pietropaolo K, Stubbings WJ, Collinson N,
- 497 Ishak L, Zrinscak B, Belanger B, Granier C, Lin K, C Hurt A, Zhou X-J, Wildum S, Hammond
- 498 J. Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19
- in an outpatient setting (MORNINGSKY). Future Virology doi:10.2217/fvl-2023-0115.
- 500 31. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. 1990. Azithromycin
- 501 concentrations at the sites of pulmonary infection. Eur Respir J 3:886-90.





Α

